Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
John Stuelpnagel
AddedFeb 13, 2024
UpdatedJun 28, 2026
John Stuelpnagel

John Stuelpnagel

Co-Founder, Illumina

CrunchbaseLinkedInThe Org

John Stuelpnagel's Career

Illumina
Illumina

San Diego, CA, US

Co-Founder
Federation Bio
Federation Bio

South San Francisco, CA, US

Board Member· Board
Encoded Therapeutics
Encoded Therapeutics

South San Francisco, CA, US

Board Member· Board
Element Biosciences
Element Biosciences

San Diego, CA, US

Board Member· Board
10x Genomics
10x Genomics

Pleasanton, CA, US

Board Member· Board
Inscripta
Inscripta

Boulder, CO, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

John Stuelpnagel's Career

Illumina
Illumina
Public$778M11.5k1998San Diego, CA, US
Co-Founder

Leadership at Illumina

John ThompsonJohn ThompsonBoard Member
Gary GuthartGary GuthartBoard Member
Jacob ThaysenJacob ThaysenBoard Member
Philip SchillerPhilip SchillerBoard Member
Larry BockLarry BockCo-Founder
Jay FlatleyJay FlatleyBoard Member

Similar to Illumina

10x Genomics10x GenomicsPleasanton, CA, USGene Sequencingest. 201210x GenomicsPleasanton, CA, US · est. 2012

10x Genomics: A leading American biotech firm, innovating in gene sequencing since 2012.

Public · $242.6M448
Element BiosciencesElement BiosciencesSan Diego, CA, USGenetic Analysis Toolsest. 2017Element BiosciencesSan Diego, CA, US · est. 2017

San Diego-based biotech firm specializing in the development of genetic analysis tools.

Series C · $401M348
Bionano GenomicsBionano GenomicsSan Diego, CA, USGenome Mapping, Softwareest. 2003Bionano GenomicsSan Diego, CA, US · est. 2003

Bionano Genomics, based in San Diego, offers advanced genome mapping and structural variation detection.

Public · $288.1M405
Federation Bio
Federation Bio
Series A$50M462019South San Francisco, CA, US
Board Member· Board

Recent news

Indian drone startup Raphe mPhibr raises $100M as military UAV demand soarsTechCrunch · 2025

Leadership at Federation Bio

Patrick ZhangPatrick ZhangBoard Member
Racquel BrackenRacquel BrackenCo-Founder
Dylan DoddDylan DoddCo-Founder
Michael FischbachMichael FischbachBoard Member
Emily Drabant ConleyEmily Drabant ConleyCEO

Similar to Federation Bio

MarvelBiomeMarvelBiomeWoburn, MA, USTherapeuticsest. 2019MarvelBiomeWoburn, MA, US · est. 2019

MarvelBiome: A biopharmaceutical company harnessing microbial power for innovative disease treatments.

Seed · $3.1M9
Naked BiomeNaked BiomeCacheu Region, GWTherapeuticsest. 2015Naked BiomeCacheu Region, GW · est. 2015

Naked Biome: A therapeutics company advancing microbiome-based treatments for skin diseases.

Seed · $11.1M1
Encoded Therapeutics
Encoded Therapeutics
Series D$239.1M2002014South San Francisco, CA, US
Board Member· Board

Leadership at Encoded Therapeutics

Karan TakharKaran TakharBoard Member
Sean NolanSean NolanBoard Member
Kartik RamamoorthiKartik RamamoorthiBoard Member
Stephanie TagliatelaStephanie TagliatelaBoard Member
Element Biosciences
Element Biosciences
Series C$401M3482017San Diego, CA, US
Board Member· Board

Leadership at Element Biosciences

Molly HeMolly HeBoard Member
Michael PreviteMichael PreviteCo-Founder
JAMES BRUCE TANANBAUMJAMES BRUCE TANANBAUMBoard Member

Similar to Element Biosciences

BioDatomicsBioDatomicsBethesda, MD, USSoftwareest. 2010BioDatomicsBethesda, MD, US · est. 2010

BioDatomics: Advanced software tool for omics research, simplifying complex bio-research since 2010.

Seed · $1.5M30
BioSkryb GenomicsBioSkryb GenomicsDurham, NC, USGenomic Toolsest. 2018BioSkryb GenomicsDurham, NC, US · est. 2018

BioSkryb Genomics: Transforming single cell discovery with advanced genomic tools for disease management.

Series A · $31.5M83
10x Genomics
10x Genomics
Public$242.6M4482012Pleasanton, CA, US
Board Member· Board

Recent news

Genetics testing startup Nucleus Genomics criticized for its embryo product: ‘Makes me so nauseous’Startups | TechCrunch · 2025
Promise Bio exits stealth backed by Pfizer and AstraZenecaTechCrunch · 2024

Leadership at 10x Genomics

Ben HindsonBen HindsonBoard Member
Bryan RobertsBryan RobertsBoard Member
Shehnaaz SulimanShehnaaz SulimanBoard Member
Sri KosarajuSri KosarajuBoard Member
Paul ConleyPaul ConleyBoard Member
Serge SaxonovSerge SaxonovCo-Founder

Similar to 10x Genomics

XGenomesXGenomesCambridge, MA, USDNA Sequencingest. 2017XGenomesCambridge, MA, US · est. 2017

XGenomes: Revolutionizing DNA sequencing with fast, accurate, and affordable technology for health monitoring.

Angel · $350k9
Inscripta
Inscripta
Series A$463.9M1782015Boulder, CO, US
Board Member· Board

Leadership at Inscripta

Ryan T. GillRyan T. GillCo-Founder
Roger WyseRoger WyseBoard Member
Andrew GarstAndrew GarstCo-Founder
Tanya WarneckeTanya WarneckeCo-Founder

Similar to Inscripta

Mammoth BiosciencesMammoth BiosciencesSan Francisco, CA, USCrispr Productsest. 2017Mammoth BiosciencesSan Francisco, CA, US · est. 2017

Mammoth Biosciences: An American biotech firm innovating CRISPR products to improve lives.

Series D · $264.5M195
Ginkgo BioworksGinkgo BioworksBoston, MA, USOrganism Designest. 2009Ginkgo BioworksBoston, MA, US · est. 2009

Ginkgo Bioworks: Engineering biology, designing custom organisms for diverse markets.

Public · $1.6B1.3k
Tome BiosciencesTome BiosciencesWatertown, MA, USGene Editingest. 2021Tome BiosciencesWatertown, MA, US · est. 2021

Tome Biosciences: Pioneering programmable gene insertion via CRISPR for precise genome editing.

Series A · $213M88

John Stuelpnagel's Co-Investors

Anne WojcickiAnne WojcickiCo-invested · Volta Labs, Inc. Series APaul McEwanPaul McEwanCo-invested · Volta Labs, Inc. Series A

John Stuelpnagel's Similar Executives & Operators

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance Retail

People Similar to John Stuelpnagel

Juan EnriquezJuan EnriquezFounder & CEO · BiotechonomyJohannes FruehaufJohannes FruehaufCo-Founder · Mission BioCapitalMarcus Meadows-SmithMarcus Meadows-SmithBoard Member · Crop EnhancementMichael FonsteinMichael FonsteinBoard Member · Quad M SolutionsChris ViehbacherChris ViehbacherBoard Member · Before Brands